Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this report, an 18-year-old female with trichotillomania was successfully treated using the glutamate modulator n-acetylcysteine.

In this study, researchers observed that dormant TRP-2+ melanoma cells in bone marrow can interact with CD8+ T cells in tumor-bearing ret transgenic mice, potentially influencing immune responses.

This study showed that coexpression of TG2 and Gbx1 in the epidermis is necessary for esophagus-like mucosal transdifferentiation, with TGF-beta2 in the dermis essential for the process through epithelial-mesenchymal interaction.

In a mouse model, this study found that LAM/TSC cells invaded the uterus and increased angiogenesis, while anti-EGFR antibody and rapamycin effectively reduced cell presence and blood vessel proliferation.

This figure in the publication investigates the relationship between expression levels and tumor burden but reports no specific findings or conclusions.

In this study, authors reported that reflectance confocal microscopy may aid in diagnosing trichofolliculoma by identifying specific features correlated with histopathology that can be difficult to discern with other methods.

This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.

This review discusses treatment options for trichotillomania, focusing on cognitive-behavioral interventions and promising developments in combined pharmacotherapy and therapy approaches, but reports no new findings.

This study identifies a mechanism where dsRNA activates TLR3 to induce RA production, promoting hair follicle regeneration in mice and suggesting a potential role in human tissue regeneration.

This study observed that conjugates of the anticancer drug raltitrexed with dextran and albumin were more cytotoxic than the free drug at high concentrations, altering cell cycle effects.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This study suggests that testosterone may reduce knee joint range of motion by acting on relaxin receptors in rats, while flutamide and finasteride counteracted this effect and increased receptor expression.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This study found that group behavior therapy for trichotillomania led to greater short-term symptom improvement compared to supportive therapy, but did not achieve clinically significant changes or prevent relapse over six months.

This article reviews confocal microscopy findings in trichoepithelioma and desmoplastic trichoepithelioma, noting similarities with histological features, but it provides no new clinical results.

This case study reports a near-complete response of a proliferating trichilemmal tumor to neoadjuvant radiotherapy in a 79-year-old woman, highlighting radiotherapy's role in managing this condition when patients are unsuitable for surgery.

This study describes a new radiation method called three-dimensional moving field radiation therapy, which showed improved tumor targeting and reduced damage to surrounding tissues compared to traditional one-plane methods.

This study found that SMR-2 and SMR-6, analogs of retinoic acid and retinol, were approximately 100 times more toxic than retinoic acid in mice, inducing hypervitaminosis A and affecting various organs and tissues.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

This study found that a single injection of Platelet Rich Stroma improved knee function and reduced pain and stiffness in patients with knee osteoarthritis over twelve months.

This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

In this study, researchers reviewed current treatments for trichotillomania and found that psychotherapy, particularly cognitive-behavioral therapy like habit reversal training, is most effective, with some medications helping to alleviate symptoms, though further study is needed on their use.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study found that strontium ranelate promotes cartilage regeneration in rats by enhancing chondrogenic differentiation of bone mesenchymal stem cells while inhibiting the Wnt/β-catenin signaling pathway.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.